Dubuque Bank & Trust Co. Takes Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Dubuque Bank & Trust Co. purchased a new stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,100 shares of the biopharmaceutical company’s stock, valued at approximately $167,000.

A number of other hedge funds also recently made changes to their positions in SAGE. Ameritas Investment Partners Inc. bought a new stake in shares of Sage Therapeutics during the first quarter valued at approximately $180,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Sage Therapeutics during the first quarter valued at approximately $202,000. BlueCrest Capital Management Ltd bought a new stake in shares of Sage Therapeutics during the first quarter valued at approximately $205,000. Jane Street Group LLC bought a new stake in shares of Sage Therapeutics during the first quarter valued at approximately $208,000. Finally, Neuberger Berman Group LLC bought a new stake in shares of Sage Therapeutics during the first quarter valued at approximately $213,000.

Sage Therapeutics, Inc. (NASDAQ SAGE) traded down 0.46% during midday trading on Friday, reaching $80.88. The company had a trading volume of 311,577 shares. The stock has a 50-day moving average price of $82.25 and a 200 day moving average price of $71.41. The company’s market capitalization is $3.03 billion. Sage Therapeutics, Inc. has a 12-month low of $36.01 and a 12-month high of $90.43.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by $0.25. During the same quarter in the prior year, the business earned ($1.08) earnings per share. Equities analysts forecast that Sage Therapeutics, Inc. will post ($7.38) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Dubuque Bank & Trust Co. Takes Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)” was published by BNB Daily and is the property of of BNB Daily. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.baseball-news-blog.com/2017/08/19/dubuque-bank-trust-co-acquires-new-position-in-sage-therapeutics-inc-nasdaqsage-updated-updated-updated.html.

A number of research firms have commented on SAGE. Needham & Company LLC set a $95.00 price objective on Sage Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 4th. HC Wainwright boosted their price objective on Sage Therapeutics to $86.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Cowen and Company reissued a “buy” rating and issued a $100.00 price objective on shares of Sage Therapeutics in a research note on Friday, August 4th. BidaskClub lowered Sage Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Canaccord Genuity set a $110.00 price objective on Sage Therapeutics and gave the stock a “buy” rating in a research note on Saturday, August 5th. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. Sage Therapeutics presently has a consensus rating of “Buy” and an average target price of $89.64.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply